Defining novel pathways that arrest genetically unstable tetraploid cells
定义阻止遗传不稳定四倍体细胞的新途径
基本信息
- 批准号:8722136
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-16 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvisory CommitteesAgarApplications GrantsAreaAwardBiochemicalBioinformaticsBiologicalBiological AssayCandidate Disease GeneCell CycleCell Cycle ArrestCell Cycle ProgressionCell ProliferationCell divisionCellsCellular biologyCommittee MembersCytokinesisCytoskeletonDNA DamageDana-Farber Cancer InstituteDataDefectDevelopmentEnvironmentEnzymesFacultyFailureFluorescence MicroscopyFoundationsFutureG1 ArrestGene Expression ProfilingGenesGoalsGrowthHousingHumanHuman Cell LineIn VitroIndividualInstitutionLeadMDM2 geneMalignant NeoplasmsMass Spectrum AnalysisMedialMedicalMentorsMicroarray AnalysisMitosisMutateNaturePathway interactionsPediatric OncologyPhasePositioning AttributeProliferatingProtein BiochemistryProteinsPublicationsRNA InterferenceRegulationResearchResearch PersonnelResearch TrainingResourcesRoleSchoolsScreening ResultSignal PathwaySignal TransductionSmall Interfering RNASorting - Cell MovementStressSystemTestingTetraploidyTimeTrainingTumor SuppressionTumor Suppressor ProteinsUbiquitinWorkabstractingbasecancer cellcancer therapycancer typecareerexperiencefeedinggenome wide association studygenome-widein vitro activityin vivoinnovationinterestmeetingsmouse modelnoveloverexpressionpreventprogramsresearch studyresponsescreeningtumortumorigenesis
项目摘要
Project Summary/Abstract
Research: Tetraploid cells, which are a common byproduct of cell division failures, are genetically unstable
and have the capacity to facilitate tumorigenesis. Consequently, cells possess p53-dependent tumor
suppression mechanisms that limit the further proliferation of these cells by promoting a durable G1 cell cycle
arrest. However, unlike other common cellular insults that activate p53 and promote G1 arrest, such as the
DNA damage response, the mechanisms governing G1 arrest in response to tetraploidy remain largely
unexplored. A major goal of this proposal is to uncover how cells 'sense' cellular changes associated with
tetraploidy and then relay that information into the p53 pathway to prevent cell cycle progression. To address
this fundamental question, I have developed a novel genome-wide RNAi screening assay to comprehensively
identify proteins that are necessary to activate or maintain G1 cell cycle arrest after cytokinesis failure and the
induction of tetraploidy. Results from this screen, in combination with complementary bioinformatic and
biochemical approaches, will illuminate the nature of the stresses associated with tetraploidy: this includes
identifying how these stresses are sensed, how they feed into signaling cascades that activate p53, and how
they are ultimately overcome by cancer cells. Strong gene hits from this screen will be examined to determine
if they are similarly required to activate G1 arrest in response to other common cellular defects, and whether
they are commonly lost or mutated in human cancers. Ultimately, the most interesting candidates genes will
be tested for tumor suppressive activities in vitro and in vivo. Overall, the aims described in this proposal have
strong potential to identify the cellular defects associated with tetraploidy, as well as to uncover novel
regulatory mechanisms of p53. Moreover, this work may also lead to the identification of new pathways that
can be targeted by chemotherapeutics to reinforce G1 arrest in abnormal cancer cells.
Candidate Career Goals: My long-term career goal is to obtain a tenure-track faculty position at a leading
academic institution and establish a lab that is at the forefront of unraveling the many mysteries of cell cycle
progression. In particular, I have noticed a great divide in the approaches used by cell biologists and
cancer biologists to understand both the causes and consequences of cancer: in my lab, I plan on bridging
this gap by combining my pre-existing cell biological expertise with the new training opportunities in
genome-wide screening, bioinformatics, and transformation assays described in this proposal. Ultimately,
my aim is to blend these two fields in order to take a unique multifaceted experimental approach to probe
the detailed mechanisms governing cell cycle progression. The K99/R00 award will provide the protected
time I need for focused advanced training in order to achieve this career goal. I expect the mentored phase
of this proposal, which includes completing the genome-wide screen and characterizing novel pathways that
regulate p53, to take 1-2 years and result in at least one high quality publication. The following independent
phase of the award will then permit me to further explore the activation and regulation of these signaling
pathways, as well as to uncover new tumor suppressor pathways. Together, these data will be used to
justify future studies proposed in an RO1 grant application that I expect to submit at the beginning of the
third year of the independent phase.
Environment: The Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI) and
Harvard Medial School has an internationally recognized research program that houses a number of expert
researchers in the areas of cell proliferation, tumorigenesis, and cancer cell biology. I have assembled a
stellar mentoring and advisory committee (Dr. David Pellman, Dr. William Kaelin, Dr. Ron Depinho, Dr. Matt
Meyerson, and Dr. William Hahn) that will greatly benefit my research and training experience. I will meet
with members of this committee informally as needed for specific scientific or experimental advice, and
formally twice a year to discuss the general progress of my project, identify key future directions, and plan
for my transition to independence. In addition, the Harvard Medical Area has all of the necessary physical
resources required to for me to complete the proposed training and research studies, including facilities for
FACS sorting, mass spectrometry, microarray analysis, and genome-wide screening.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NEIL J. GANEM其他文献
NEIL J. GANEM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NEIL J. GANEM', 18)}}的其他基金
Mechanisms of cell proliferation in whole-genome doubled cells
全基因组加倍细胞的细胞增殖机制
- 批准号:
10467183 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Mechanisms of cell proliferation in whole-genome doubled cells
全基因组加倍细胞的细胞增殖机制
- 批准号:
10796612 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Mechanisms of cell proliferation in whole-genome doubled cells
全基因组加倍细胞的细胞增殖机制
- 批准号:
10612928 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Maintenance of Chromosome Stability by the Hippo Tumor Suppressor Pathway
Hippo 肿瘤抑制途径维持染色体稳定性
- 批准号:
9175493 - 财政年份:2016
- 资助金额:
$ 24.9万 - 项目类别:
Defining novel pathways that arrest genetically unstable tetraploid cells
定义阻止遗传不稳定四倍体细胞的新途径
- 批准号:
8321030 - 财政年份:2011
- 资助金额:
$ 24.9万 - 项目类别:
Defining novel pathways that arrest genetically unstable tetraploid cells
定义阻止遗传不稳定四倍体细胞的新途径
- 批准号:
8726938 - 财政年份:2011
- 资助金额:
$ 24.9万 - 项目类别:
Defining novel pathways that arrest genetically unstable tetraploid cells
定义阻止遗传不稳定四倍体细胞的新途径
- 批准号:
8027587 - 财政年份:2011
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant